Список литературы

1. Neufeld E., Muenzer J. The mucopolysaccharidoses//In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8 ed. New York. NY: McGraw-Hill. 2001. P. 3421 - 52.

2. Giugliani R., Federhen A., Rojas M.V. et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment//Genet Mol Biol. 2010. V. 33. N 4. P. 589 - 604.

3. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders//JAMA. 1999. V. 281. P. 249 - 54.

4. Khan S. A., Peracha H., Ballhausen D., Wiesbauer A., Rohrbach M., Gautschi M., Mason R. W., Giugliani R., Suzuk Y., Orii K. E., Orii T., Tomatsu S. Epidemiology of mucopolysaccharidoses//Molec. Genet. Metab. 2017. V. 121. P. 227 - 40.

5. Costa-Motta F.M., Bender F., Acosta A., , Machado T., Bomfim T., Boa Sorte T., da Silva D., Bittles A., Giugliani R., Leistner-Segal S. A community-based study of mucopolysaccharidosis type VI in Brazil: the influence of founder effect, endogamy and consanguinity//Hum Hered. 2014. V. 77. N 1 - 4. P. 189 - 96.

6. Valayannopoulos V., Nicely H., Harmatz P., Turbeville S. Mucopolysaccharidosis VI//Orphanet J Rare Dis. 2010. V. 5. P. 5. doi: 10.1186/1750-1172-5-5.

7. Giugliani R., Lampe C., Guffon N. et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study//American Journal of Medical Genetics, Part A. 2014. V. 164. N 8. P. 1953 - 64.

8. Horovitz D. D. G., T. de S. P. C., Costa A. P. et al. Spinal cord compression in young children with type VI mucopolysaccharidosis//Molecular Genetics and Metabolism. 2011. V. 104. N 3. P. 295 - 300.

9. White K. K., Harmatz P. Orthopedic management of mucopolysaccharide disease//Journal of Pediatric Rehabilitation Medicine. 2010. V. 3. N 1. P. 47 - 56.

10. Williams N., Challoumas D., and Eastwood D. M. Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?//Journal of Children"s Orthopaedics. 2017. V. 11. N 4. P. 289 - 97.

11. Моисеев С.В., Новиков П.И., Мешков А.Д., Фомин В.В. Мукополисахаридоз VI типа у взрослых//Клиническая фармакология и терапия. 2017. Т. 26. N 1. С. 1 - 7.

12. Golda A., Jurecka A., Tylki-Szymanska A. Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)//International Journal of Cardiology. 2012. V. 158. N 1. P. 6 - 11.

13. Lachman R. S., Burton B. K., Clarke L. A. et al. Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): Under-recognized and challenging to diagnose//Skeletal Radiology. 2014. V. 43. N 3. P. 359 - 69.

14. Wood T., Bodamer O. A., Burin M. G. et al. Expert recommendations for the laboratory diagnosis of MPS VI//Molecular Genetics and Metabolism. 2012. V. 106. N 1. P. 73 - 82.

15. Human Gene Mutations Database. Qiagen HGMD Professional

16. Giugliani P. H., Wraith J. E. Management Guidelines for Mucopolysaccharidosis VI//Pediatrics. 2007. V. 120. N 2. P. 405 - 18.

17. Hendriksz C. J. et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)//Journal of inherited metabolic disease. 2013. V. 36. N 2. P. 373 - 84.

18. Giugliani R., Herber S., Pinto L. L. D. C., Baldo G. Therapy for Mucopolysaccharidosis VI: (Maroteaux-Lamy Syndrome) Present Status and Prospects//Pediatric Endocrinology Reviews: Diabetes Nutrition Metabolism Genetics. 2014. V. 12. Suppl. 1. P. 152 - 58.

19. Brunelli M.J., , da Silva EMK. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI//Cochrane Database of Systematic Reviews. 2016. Issue 3. Art. No.: CD009806.

20. Harmatz P., Whitley C.B., Waber L. et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)//J Pediatr. 2000. V. 144. N 5. P. 574 - 80.

21. Harmatz P., Giugliani R., Ida I. V., Guffon N., et all. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase//Molecular Genetics and Metabolism. 2008. V. 94. N 4. P. 469 - 75.

22. Swiedler S. J., Beck M., Bajbouj M. et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)//American Journal of Medical Genetics. 2005. V. 134 A(2). P. 144 - 50.

23. Brands M. M. G., , van den Hout J. M. P. et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey//Journal of Inherited Metabolic Disease. 2015. V. 38. N 2. P. 323 - 31.

24. Kampmann C., Lampe C., , Wiethoff C. M., Mengel E., Arash L., Beck M., Miebach E. Mucopolysaccharidosis VI: Cardiac involvement and the impact of enzyme replacement therapy//Journal of Inherited Metabolic Disease. 2014. V. 37. N 2. P. 269 - 76.

25. Lampe C., . Craniocervical decompression in patients with mucopolysaccharidosis VI: development of a scoring system to determine indication and outcome of surgery//J Inherit Metab Dis. 2013. V. 36. N 6. P. 1005 - 13.

26. Lampe C., Lampe C., Schwarz M., , Harmatz P., Mengel E. Craniocervical decompression in patients with mucopolysaccharidosis VI: Development of a scoring system to determine indication and outcome of surgery//Journal of Inherited Metabolic Disease. 2013. V. 36. N 6. P. 1005 - 13.

27. Leal G. N., De Paula A. C., Leone C., Kim C. A. Echocardiographic study of pediatric patients with mucopolysaccharidosis//Cardiology in the Young. 2010. V. 20. N 3. P. 254 - 61.

28. Moreira G. A., Kyosen S. O., Patti C. L., Martins A. M., Tufik S. Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center//Sleep and Breathing. 2014. V. 18. N 4. P. 791 - 97.

29. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses//Rheumatology (Oxford). 2011. V. 50. N 5. P. 49 - 59.

30. Миронов С.П., Колесов С.В., Переверзев В.С., Колбовский Д.А., Кулешов А.А., Ветрилэ М.С., Казьмин А.И. Опыт хирургического лечения краниовертебрального стеноза у пациентов с мукополисахаридозом I, II, VI типов//Хирургия позвоночника. 2018. Т. 15. N 4. С. 32 - 40.

31. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders//International journal of clinical pharmacology and therapeutics. 2009. V. 47. P. S100 - 6.

32. Yuen A. et al. Carpal tunnel syndrome in children with mucopolysaccaridoses//Journal of child neurology. 2007. V. 22. N 3. P. 260 - 3.

33. Alden T. D. et al. Surgical management of neurological manifestations of mucopolysaccharidosis disorders//Molecular Genetics and Metabolism. 2017. V. 122. P. 41 - 8.

34. White K. K. Orthopaedic surgery for mucopolysaccharidosis//Current Orthopaedic Practice. 2012. V. 23. N 5. P. 394 - 9.